Beam Therapeutics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Beam Therapeutics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $24.0K | Mar 15, 2021 |
| FY2020 | Dec 31, 2019 | $18.0K | Mar 15, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $139.74M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $63.52M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $377.71M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $60.92M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $51.84M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $24.0K | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $18.0K | Feb 28, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.99M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($376.74M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($132.53M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($289.09M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($370.64M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($194.59M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($78.33M) | Feb 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($383.69M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($415.57M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($176.49M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($338.48M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($392.47M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($132.76M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($75.15M) | Feb 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $409.62M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $367.56M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $437.38M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $311.59M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $387.09M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $103.18M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $54.62M | Feb 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($345.10M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($347.25M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($149.20M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $22.53M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($66.27M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($95.74M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($72.00M) | Feb 28, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.95M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $8.95M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $33.73M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $48.95M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $46.81M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $16.36M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $12.52M | Feb 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.46B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.34B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.47B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $451.68M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $156.10M | Mar 15, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $242.82M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $370.28M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $478.39M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $608.24M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $647.72M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $206.12M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $55.15M | Mar 15, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $733.55M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $981.33M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $733.47M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $826.74M | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $245.56M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | ($201.10M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($117.41M) | Feb 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.64B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($1.57B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($1.19B) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($1.06B) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($768.27M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($397.64M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($203.04M) | Mar 15, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $294.94M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $281.97M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $435.90M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $232.77M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $559.99M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $162.17M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $37.22M | Feb 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (4) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (14) | Feb 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (4) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (14) | Feb 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 101.75M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 83.63M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 81.63M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 71.28M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 68.39M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 57.25M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 7.33M | Mar 15, 2021 |